Jiangsu Hengrui Medicine’s subsidiary Beijing Shengdi Pharmaceutical received an acceptance notice from the National Medical Products Administration (NMPA) for the marketing-authorisation application of SHR-2004 injection, a Class 1 innovative coagul

2026-09-14

Jiangsu Hengrui Medicine’s subsidiary Beijing Shengdi Pharmaceutical received an acceptance notice from the National Medical Products Administration (NMPA) for the marketing-authorisation application of SHR-2004 injection, a Class 1 innovative coagulation factor XI (FXI) monoclonal antibody.